• Center believes the CyberKnife System is the #1 tool for delivery of advanced radiosurgery treatments
• Selected the latest generation CyberKnife S7™ System to increase the number of indications they can treat throughout the body, and the patients they can help

SUNNYVALE, Calif., Jan. 26, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the European Radiosurgery Center Munich has selected a second CyberKnife^® System, the latest generation CyberKnife S7™ System, to enable their team to treat the high volume of patients they see in their practice who would benefit from the extremely precise radiation treatments it delivers. The Center was an early adopter of CyberKnife radiosurgery and continues to pioneer new ways to use the system in the non-invasive treatment of certain neurological conditions and tumors.

With almost 18 years of experience using the CyberKnife platform and more than 10,000 patients treated, the European Radiosurgery Center Munich team is one of the foremost experts in the delivery of radiosurgery treatments – a technique in which very focused, high doses of radiation are delivered to a specific area of the body over a short period of time. This out-patient treatment process necessitates an extremely high degree of precision and accuracy. Patients eligible for radiosurgery treatments benefit from the shorter overall course of care, typically 1 to 2 sessions in Munich, compared to conventional radiation therapy which often requires 30-40 sessions, and experience less disruption to their daily lives.

"Our team in Munich is thrilled to enhance our CyberKnife capabilities with the newest generation of the system. I believe that CyberKnife is the #1 technology in the field for delivering radiosurgery, our preferred approach when appropriate for our patients," said Prof. Dr. Alexander Muacevic, Director European Radiosurgery Center Munich. "The volume of patients we see who would benefit from treatment far exceeds our ability to provide care with our current system so we made the decision to focus on select tumor types. The installation of an additional system will enable our team to treat a wider range of cases, particularly those in the body, extending the benefits – of CyberKnife and radiosurgery – to more patients."

The CyberKnife S7 System was designed to provide clinicians with the speed required for workflow efficiency while maintaining the precision and accuracy required for radiosurgery treatments. The Accuray exclusive Synchrony^® technology enables the system to continually track and automatically correct the beam for patient or tumor movement in real-time throughout the entire treatment session.

Suzanne Winter, president and CEO of Accuray said, "We are grateful for the long-term trust of Prof. Dr. Muacevic and his team in our company and products. I believe the CyberKnife S7 System's unique capabilities align with their goals – and the healthcare community's – to deliver better, faster care that enables patients to get back to living their lives more quickly.

"The European Radiosurgery Center Munich team, through their commitment to continually revolutionizing radiosurgery, has established a protocol for delivering treatments using the CyberKnife System that has enriched the lives of thousands of patients over almost two decades. Their achievements demonstrate what is possible when an expert medical care team is partnered with the right technology."

Important Safety Information

For Important Safety Information please refer to https://www.accuray.com/safety-statement.

About Accuray

Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter, and YouTube.

Safe Harbor Statement

Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient experiences and patient outcomes. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products, including new product innovations and releases; the company's ability to develop new products or improve existing products to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace; and the direction of technological innovation and customer demands and such other risks identified under the heading "Risk Factors" in the company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on November 3, 2022, and as updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Media Contact
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
This email address is being protected from spambots. You need JavaScript enabled to view it.